<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126776">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451996</url>
  </required_header>
  <id_info>
    <org_study_id>16171A</org_study_id>
    <nct_id>NCT01451996</nct_id>
  </id_info>
  <brief_title>The Efficacy of Claritin in Healthy Subjects</brief_title>
  <official_title>The Efficacy of Claritin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine determinants of the efficacy of Claritin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be given Claritin 10mg tablet. Subjects will be challenged with histamine via
      skin prick prior to Claritin administration and at 1 and 2 hours post administration. We
      will measure and record wheal and flare area 10 minutes following each challenge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in wheal area following the baseline and time 2:00 challenges</measure>
    <time_frame>Wheal area is assessed at baseline and 2 hours post administration of Claritin.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in wheal area following the baseline and time 1:00 challenges</measure>
    <time_frame>Wheal area is assessed at baseline and 1 hours post administration of Claritin</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">490</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Claritin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject will be given 10mg Claritin tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Claritin</intervention_name>
    <description>Subject will be given 10mg Claritin tablet.</description>
    <arm_group_label>Claritin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.

        1. Males and females between 18 and 65 years of age.

        Exclusion Criteria.

          1. Pregnant or lactating women.

          2. Upper respiratory infection within 14 days of study start.

          3. Women of childbearing potential not using specific contraception method(s) (i.e.,
             birth control pills, depo Provera, double barrier) as well as women who are
             breastfeeding.

          4. Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study (heart, lung, kidney, neurological, oncologic or
             liver disease).

          5. Use of any other investigational agent in the last 30 days.

          6. Use of medications that may affect skin testing. Specifically, subjects are excluded
             if they have used an antihistamine during the 4 days preceding their treatment visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anup Malani, J.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>direct-to-consumer advertising</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
